title: Controlled multiple growth factor delivery from bone tissue engineering scaffolds via designed affinity.
abstract: It is known that angiogenesis plays an important role in bone regeneration and that release of angiogenic and osteogenic growth factors can enhance bone formation. Multiple growth factors play key roles in processes that lead to tissue formation/regeneration during natural tissue development and repair. Therefore, treatments aiming to mimic tissue regeneration can benefit from multiple growth factor release, and there remains a need for simple clinically relevant approaches for dual growth factor release. We hypothesized that mineral coatings could be used as a platform for controlled incorporation and release of multiple growth factors. Specifically, mineral-coated scaffolds were "dip coated" in multiple growth factor solutions, and growth factor binding and release were dictated by the growth factor-mineral binding affinity. Beta tricalcium phosphate (β-TCP) scaffolds were fabricated using indirect solid-free form fabrication techniques and coated with a thin conformal mineral layer. Mineral-coated β-TCP scaffolds were sequentially dipped in recombinant human vascular endothelial growth factor (rhVEGF) and a modular bone morphogenetic peptide, a mineral-binding version of bone morphogenetic protein 2 (BMP2), solutions to allow for the incorporation of each growth factor. The dual release profile showed sustained release of both growth factors for over more than 60 days. Scaffolds releasing either rhVEGF alone or the combination of growth factors showed an increase in blood vessel ingrowth in a dose-dependent manner in a sheep intramuscular implantation model. This approach demonstrates a "modular design" approach, in which a controllable biologics carrier is integrated into a structural scaffold as a thin surface coating.
authors.affiliation: 1 Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison , Madison, Wisconsin.
authors.forename: Darilis
authors.initials: D
authors.lastname: Suárez-González
authors.forename: Jae Sung
authors.initials: JS
authors.lastname: Lee
authors.forename: Alisha
authors.initials: A
authors.lastname: Diggs
authors.forename: Yan
authors.initials: Y
authors.lastname: Lu
authors.forename: Brett
authors.initials: B
authors.lastname: Nemke
authors.forename: Mark
authors.initials: M
authors.lastname: Markel
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Hollister
authors.forename: William L
authors.initials: WL
authors.lastname: Murphy
mesh_terms: D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology*; D002130:Calcium Phosphates / Q000494:pharmacology; D005260:Female; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects; D019919:Prosthesis Implantation; D012756:Sheep; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds / Q000737:chemistry*; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*
chemical_list: D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C485817:beta-tricalcium phosphate